Ignite Creation Date:
2025-12-25 @ 12:08 AM
Ignite Modification Date:
2026-01-11 @ 5:29 AM
Study NCT ID:
NCT00570258
Status:
TERMINATED
Last Update Posted:
2021-03-30
First Post:
2007-12-06
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Sponsor:
University of Arkansas
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-09
Start Date Type:
None
Primary Completion Date:
2010-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-12
Completion Date Type:
ACTUAL
First Submit Date:
2007-12-06
First Submit QC Date:
None
Study First Post Date:
2007-12-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-07-06
Results First Submit QC Date:
None
Results First Post Date:
2019-02-06
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-03-26
Last Update Post Date:
2021-03-30
Last Update Post Date Type:
ACTUAL